LUND, Sweden--(BUSINESS WIRE)--In this White Paper, Immunovia (STO:IMMNOV) summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates from 4-6% to 50-60%.
